Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Ataxin 7 Monoclonal Antibody (3SCA-1C1)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA3083
Description
MA3-083 detects Ataxin 7 from human and mouse samples. MA3-083 has been successfully used in Western blot, immunofluorescence, and ELISA applications. The MA3-083 epitope is mapped between aa 66 and aa 119.
Spinocerebellar ataxia type 7 (SCA7) belongs to a class of hereditary neurodegenrative diseases characterized by abnormally expanded polyglutamine (CAG) repeats at the N-terminus. This autosomal dominant cerebellar ataxia primarily affects the cerebellum, retina, and brain stem and causes dementia, macular degeneration and other neurodegenerative characteristics. SCA7 gene encodes the ubiquitous 892 residue protein ataxin-7. This protein is typically located in the cytoplasm and on the nuclear membrane of normal brain neurons. In cells where there is a mutation of the SCA7 gene, ataxin 7 accumulates in intranuclear inclusions and can result in cell death.
Specifications
Ataxin 7 | |
Monoclonal | |
Conc. Not Determined | |
Ascites with 0.05% sodium azide | |
O15265, Q8R4I1 | |
ATXN7 | |
Recombinant human Ataxin 7 aa 1 - 229. | |
RUO | |
246103, 6314 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Western Blot, Immunocytochemistry | |
3SCA-1C1 | |
Unconjugated | |
ATXN7 | |
A430107N12Rik; ADCAII; AI627028; Ataxin 7; Ataxin7; Ataxin-7; ATXN7; Atxn7-PA; Atxn7-PB; Atxn7-PC; Atxn7-PD; CG9866; CG9866-PA; CG9866-PB; CG9866-PC; CG9866-PD; Dmel\CG9866; Dmel_CG9866; LD40170p; OPCA3; RGD1562692; SCA7; spinocerebellar ataxia 7 homolog; spinocerebellar ataxia type 7 protein; Spinocerebellar ataxia type 7 protein homolog | |
Mouse | |
50 μL | |
Primary | |
Human, Mouse | |
Antibody | |
IgG1 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction